Neuromodulation is a technology that directly reacts on the nerves. It is the delivery of stimulus directly to the target area. It is very effective as it can treat almost every disease from headache to spinal cord damage. The therapy provides relief from pain and steer away the side effects. Some of its applications are spinal cord stimulation, deep brain simulation, and sacral nerve stimulation. Electrodes are attached to the brain to carry out the procedure.
Neurological disorders such as epilepsy, Alzheimer disease, cerebrovascular diseases, and Parkinson's disease affect the central and peripheral nervous system. Bacterial, viral, and fungal infections can also cause neurological disorders. To manage such disorders, neuromodulation is used, wherein small electrodes generate electrical most precise stimulation with the help of pulse generators to supplement neurological activities in effected people. The electrodes are generally placed directly in the brain or peripheral nerves or spinal cord whereas pulse generators are implanted within the skin.
image Credit: sciencedirect.com
The spinal cord stimulation has huge potential to treat widespread chronic back pain. Around 20% of adult Americans experience chronic pain. Recently, USFDA and similar regulatory agencies have approved many products of the SCS technology, for instance Senza SCS System by Nevro Corporation and Proclaim Elite SCS by St. Jude Medical. The use of technology is expanding to new indications such as failed-back surgery syndrome, refractory angina pectoris, peripheral vascular disease, and complex regional pain syndrome. Deep Brain Stimulation (DBS) market is projected to exhibit significant growth due to high adoption rate in developed economies for neurological disorders, such as Parkinson’s disease, which have no known cure. The use of DBS is expanding to new indications such as severe obsessive-compulsive disorder, treatment-resistant depression, Alzheimer's type dementia, and movement disorders.
In Japan, Pharmaceutical and Medical Devices Agency has approved numerous neurostimulators for pain management since 2010 such as Eon Mini and Genesis spinal cord stimulation (SCS) system by St. Jude and Precision Spectra by Boston Scientific. Neuromodulation is an intracranial, electrical neuromodulation therapy that has FDA approval for the treatment for most of the neurological diseases, such as bladder control, headache, tremors, chronic pain, stroke, minimally conscious state, and spinal cord injury, which are most commonly found in the elderly population.
The key players operating in the neuromodulation market are Abbott, Boston Scientific Corporation, Integer Holdings Corporation, Magstim, Medtronic, NeuroPace, Inc., NeuroSigma, Inc., Nevro Corp., Synapse Biomedical Inc., and Soterix Medical Inc. among others.
Source: The Insight Partners